(Reuters) - The ruling is less draconian in certain respects than CMS's draft proposal issued in May, but in other respects could be just as damaging to Aranesp sales, according to some analysts.
"The overall implications of the final decision are potentially worse than we anticipated with restrictions placed no only on initiation but on maintenance use of EPO for cancer as well," said Geoffrey Porges, an analyst at Sanford Bernstein.
Read more at Reuters.com Hot Stocks News
"The overall implications of the final decision are potentially worse than we anticipated with restrictions placed no only on initiation but on maintenance use of EPO for cancer as well," said Geoffrey Porges, an analyst at Sanford Bernstein.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment